Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2603076 | 0.86 | NPSR1 (0.40) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL12251143 | 0.84 | CYP19A1 (0.42) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL2603074 | 0.84 | NPSR1 (0.63) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL12936719 | 0.84 | EPHX2 (0.50) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL27436848 | 0.83 | CYP19A1 (0.53) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL2603060 | 0.82 | HSD11B1 (0.41) | CYP19A1EPHX2CYP17A1NPSR1ALDH1A1 | |
| SCHEMBL14944490 | 0.82 | DPP4 (0.40) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL27521122 | 0.81 | CYP19A1 (0.45) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL12936716 | 0.81 | EPHX2 (0.55) | CYP19A1EPHX2CYP17A1NPSR1TSHR | |
| SCHEMBL9917016 | 0.81 | CYP19A1 (0.56) | CYP19A1EPHX2CYP17A1NPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473799-B2 | Process for the preparation of synthetic retinoids with disubstituted adamantyl radical | NANJING UNIVERSITY OF AERONAUTICS AND ASTRONAUTICS (CN) | 2009-01-06 | — | — | US | claimed |
| US-20080108848-A1 | Process for the preparation of synthetic retinoids with disubstituted adamantyl radical | NANJING UNIVERSITY OF AERONAUTICS AND ASTRONAUTICS (CN) | 2008-05-08 | — | — | US | claimed |
| US-7351521-B2 | Photoresist composition for deep ultraviolet lithography | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2008-04-01 | — | — | US | claimed |
| US-20070172762-A1 | Photoresist composition for deep ultraviolet lithography | DAMMEL RALPH R | 2007-07-26 | — | — | US | claimed |
| US-20070154841-A1 | Photoresist composition for deep ultraviolet lithography | AZ ELECTRONIC MATERIALS USA CORP. | 2007-07-05 | — | — | US | claimed |
| US-7211366-B2 | Photoresist composition for deep ultraviolet lithography | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2007-05-01 | — | — | US | claimed |
| EP-1602011-A2 | PHOTORESIST COMPOSITION FOR DEEP ULTRAVIOLET LITHOGRAPHY | AZ Electronic Materials USA Corp. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004074928-A2 | PHOTORESIST COMPOSITION FOR DEEP ULTRAVIOLET LITHOGRAPHY | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040166434-A1 | Photoresist composition for deep ultraviolet lithography | AZ ELECTRONIC MATERIALS USA CORP. | 2004-08-26 | — | — | US | claimed |
| US-20040166433-A1 | Photoresist composition for deep ultraviolet lithography | AZ ELECTRONIC MATERIALS USA CORP. | 2004-08-26 | — | — | US | claimed |
| EP-0358574-B1 | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-02-17 | — | — | EP | claimed |
| US-5015758-A | Process for the preparation of 1-adamantane derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-05-14 | — | — | US | claimed |
| EP-0358574-A1 | Process for the preparation of adamantane-1 derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-03-14 | — | — | EP | claimed |
| EP-4658663-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024163262-A2 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| CN-1881084-A | Chemically amplified resist material and pattern formation method using the same | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2006-12-20 | — | — | CN | disclosed |
| EP-0358574-B1 | PROCESS FOR THE PREPARATION OF ADAMANTANE-1 DERIVATIVES | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1993-02-17 | — | — | EP | disclosed |
| US-5015758-A | Process for the preparation of 1-adamantane derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-05-14 | — | — | US | disclosed |
| EP-0358574-A1 | Process for the preparation of adamantane-1 derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287124-A1 | PRODRUGS OF 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DNTT, NAPRT, NAMPT | CYP19A1 761/4885EPHX2 1430/4885CYP17A1 1125/4885 |
| US-20080108848-A1 | Process for the preparation of synthetic retinoids with disubstituted adamantyl radical | RXRA, RARA, RXRB | CYP19A1 301/4885EPHX2 1219/4885CYP17A1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.